Through its Prevention beyond the pipeline Program, the ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
- One year for epidemiological analyses
- Varies (multi-year) for clinical trials
- $50,000-$100,000 for epidemiological analyses
- Up to $3 million for clinical trials based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Deadline for LoI: 10 July, 9 Ocotber 2020.